Keywords: enzon, pharma, drops, rhmbl, program, new, jersey

Enzon Pharma drops rhMBL program

Article | 16 February 2009

New Jersey, USA-based Enzon Pharmaceuticals has announced the discontinuation of the current recombinant human Mannose-Binding Lectin (rhMBL) clinical program, as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing